← Leaderboards
Jordan D Berlin
Vanderbilt University
$14,361,518
Attributed
$15,375,172
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2010–24$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,375,172 · 12
By mechanism
U10$3,986,565 · 2
P30$3,810,557 · 3
P50$3,041,348 · 3
UG1$1,883,053 · 1
U24$1,294,941 · 1
UM1$732,368 · 1
Top collaborators
- Henry Charles Manning2 shared
- Patricia M Lorusso1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- William M Grady$22,313,396
- Raymond Nelson Dubois$22,706,669
- Michelle G Craske$19,938,115
- Walter J Chazin$29,538,014
- Jennifer A Pietenpol$43,416,854
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsTumorMalignant NeoplasmsCancer CenterMemberClinical ResearchResearch PersonnelGrowthAreaInstitutesBerlinResource SharingLeadJordanBasic ScienceGrantMolecularFundingSourceTranslational ResearchFacultyProgramsInstitutionInnovation
Grant awards (54)
Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC$142,081
P50 · FY2024 · CA · contact PI
Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC$399,535
P50 · FY2023 · CA · contact PI
Vanderbilt Network Lead Academic Participating Site for the NCTN$507,576
UG1 · FY2022 · CA · contact PI
Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC$399,535
P50 · FY2022 · CA · contact PI
Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC$410,130
P50 · FY2021 · CA · contact PI
Vanderbilt Network Lead Academic Participating Site for the NCTN$400,925
UG1 · FY2021 · CA · contact PI
Vanderbilt Network Lead Academic Participating Site for the NCTN$487,276
UG1 · FY2020 · CA · contact PI
Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC$415,695
P50 · FY2020 · CA · contact PI
VU PREDICT$630,328
U24 · FY2019 · CA
Vanderbilt Network Lead Academic Participating Site for the NCTN$487,276
UG1 · FY2019 · CA · contact PI
Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC$400,780
P50 · FY2019 · CA · contact PI
VU PREDICT$664,613
U24 · FY2018 · CA
Vanderbilt Network Lead Academic Participating Site for the NCTN$503,410
U10 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$289,261
P30 · FY2018 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$87,030
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$10,000
P30 · FY2018 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$10,000
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$7,998
P30 · FY2018 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$7,997
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$7,969
P30 · FY2018 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$7,968
P30 · FY2018 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$4,817
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$4,817
P30 · FY2018 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$4,735
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$4,735
P30 · FY2018 · CA · contact PI
Vanderbilt Network Lead Academic Participating Site for the NCTN$592,247
U10 · FY2017 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$289,261
P30 · FY2017 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$87,030
P30 · FY2017 · CA · contact PI
ViKTriY-PC Consortium Phase II Supplement$732,368
UM1 · FY2016 · CA
Vanderbilt Network Lead Academic Participating Site for the NCTN$410,211
U10 · FY2016 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$281,051
P30 · FY2016 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$84,561
P30 · FY2016 · CA · contact PI
Vanderbilt Network Lead Academic Participating Site for the NCTN$9,808
U10 · FY2016 · CA · contact PI
Vanderbilt Network Lead Academic Participating Site for the NCTN$528,806
U10 · FY2015 · CA · contact PI
Targeting K-Ras in CRC$281,462
P50 · FY2015 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$281,051
P30 · FY2015 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)$162,333
P30 · FY2015 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$84,561
P30 · FY2015 · CA · contact PI
Gastrointestinal Cancer Research Program (GI) (Project-005)$48,839
P30 · FY2015 · CA · contact PI
Vanderbilt Network Lead Academic Participating Site for the NCTN$587,562
U10 · FY2014 · CA · contact PI
Clinical Trials Shared Resource$450,517
P30 · FY2014 · CA · contact PI
Targeting K-Ras in CRC$180,315
P50 · FY2014 · CA · contact PI
Clinical Trials Shared Resource$442,789
P30 · FY2013 · CA · contact PI
Eastern Cooperative Oncology Group$291,047
U10 · FY2013 · CA · contact PI
Targeting K-Ras in CRC$191,946
P50 · FY2013 · CA · contact PI
Clinical Trials Shared Resource$370,402
P30 · FY2012 · CA · contact PI
Eastern Cooperative Oncology Group$355,104
U10 · FY2012 · CA · contact PI
Targeting K-Ras in CRC$219,869
P50 · FY2012 · CA · contact PI
Clinical Trials Shared Resource$374,352
P30 · FY2011 · CA · contact PI
Eastern Cooperative Oncology Group$340,836
U10 · FY2011 · CA · contact PI
Clinical Trials Shared Resource$406,483
P30 · FY2010 · CA · contact PI
Eastern Cooperative Oncology Group$367,534
U10 · FY2010 · CA · contact PI
PS-341 in Hepatocellular Carcinoma: A Phase II Trial$312,833
R21 · FY2004 · CA
PS-341 in Hepatocellular Carcinoma: A Phase II Trial$313,507
R21 · FY2003 · CA